time to confirmed deterioration
Figure 1 · Panel Kaplan-Meier_estimate_of_TTD_for_EORTC_QLQ-C30_GHS_QoL_score
Panel Kaplan-Meier_estimate_of_TTD_for_EORTC_QLQ-C30_GHS_QoL_score 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
R S Finn, M Kudo, P Merle, T Meyer, S Qin, M Ikeda, R Xu, J Edeline, B-Y Ryoo, Z Ren, A-L Cheng, P R Galle, S Kaneko, H Kumada, S Kamble, J M Norquist, K Mody, A Wang, L Dubrovsky, J M Llovet
ESMO Open 10(6) 105065
BACKGROUND: Patients with advanced hepatocellular carcinoma (HCC) have a substantial symptom burden that affects their health-related quality of life (HRQoL). Assessing the impact of first-line regimens on HRQoL is essential to evaluate clinical benefit in addition to efficacy and safety in this setting. METHODS: LEAP-002 is a randomized phase III trial of lenvatinib plus pembrolizumab versus lenvatinib plus placebo as first-line treatment for participants with advanced HCC. Patient-reported outcomes (PROs) were prespecified exploratory endpoints assessed in all participants randomly assigned to treatment using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 questionnaire (EORTC QLQ-C30), EORTC QLQ Hepatocellular Carcinoma 18-item module (EORTC QLQ-HCC18), and EuroQol 5-dimension, 5-level questionnaire (EQ-5D-5L) at baseline and throughout the trial. Median time to confirmed deterioration (TTD) in PROs was estimated using the Kaplan-Meier method. Least-squares mean change from baseline to week 27 (latest time point when completion and compliance rates were ≥60% and ≥80%, respectively) in PRO scores was assessed using a constrained longitudinal data analysis model. No formal hypotheses were tested. RESULTS: The PRO population comprised 779 participants (lenvatinib plus pembrolizumab, n = 390; lenvatinib plus placebo, n = 389). Completion rates for all PRO assessments were >94% at baseline and >63% at week 27. Median TTD for EORTC QLQ-C30 global health status/quality-of-life score was 11.5 months [95% confidence interval (CI) 5.6 months-not reached] in the lenvatinib plus pembrolizumab group and 4.3 months (95% CI 3.5-5.5 months) in the lenvatinib plus placebo group (hazard ratio 0.80, 95% CI 0.65-0.98). TTD and least-squares mean change from baseline to week 27 were similar between treatment groups for EORTC QLQ-C30 scales, EORTC QLQ-HCC18 scores, and the EQ-5D-5L visual analog scale. CONCLUSION: Adding pembrolizumab to lenvatinib, which is a current first-line option as a single agent, maintained HRQoL during the first-line treatment of participants with advanced HCC.
1 个 Figure · 1 个 KM 面板
Figure 1 Kaplan–Meier estimate of TTD for EORTC QLQ-C30 GHS/QoL score . CI, confidence interval; EORTC, European Organisation for Research and Treatment of Cancer; GHS, global health status; HR, hazard ratio; NR, not reached; QLQ-C30, QoL Questionnaire Core 30; QoL, quality of life; TTD, time to confirmed deterioration.
Figure 1 · Panel Kaplan-Meier_estimate_of_TTD_for_EORTC_QLQ-C30_GHS_QoL_score
Panel Kaplan-Meier_estimate_of_TTD_for_EORTC_QLQ-C30_GHS_QoL_score 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。